About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $100 million of its common stock. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million in shares of its common stock on the same terms and condi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 CANDEL THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 117 Kendrick St Suite 450 Needham, Massachusetts 02494 (Address of Principal Executive Offices) (Zip Code) Delaware 001-40629 52-2214851 (Commission ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer                   Royalties based on annual net sales of aglatimagene in the U.S.Funds will strengthen the Company’s balance sheet for potential U.S. commercial launch of aglatimagene in intermediate- to high-risk localized prostate cancer NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel ...

Core Insights - Candel Therapeutics, Inc. is focused on developing multimodal biological immunotherapies for cancer treatment and will present at the 7th Annual Glioblastoma Drug Development Summit in February 2026 [1] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] - The lead product candidate from the adenovirus platform is aglatimagene besadenovec (CAN-2409), which has completed successful phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is undergoing a pivotal phase 3 trial in localized prostate cancer [4] Product Development - Linoserpaturev (CAN-3110) is the lead candidate from the HSV platform, currently in a phase 1b clinical trial for recurrent high-grade glioma [5] - In October 2023, results from a clinical trial indicated that linoserpaturev was well tolerated with no dose-limiting toxicity, showing improved median overall survival compared to historical controls after a single injection [3] - The company is supported by the Break Through Cancer foundation to evaluate repeated linoserpaturev injections in patients with recurrent glioblastoma [3] Upcoming Presentations - Dr. Francesca Barone will present insights on Candel's HSV-based platform and the linoserpaturev program at the summit, including a workshop on patient stratification and a conference presentation on integrating biomarkers and imaging [2][3]

NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company’s common stock, with a per share exercise price of ...

Group 1 - U.S. stocks showed mixed performance, with the Dow Jones increasing by over 600 points on Thursday [1] - Diamond Hill Investment Group Inc's shares surged 45.3% to $170.74 after First Eagle announced an acquisition for $175 per share in a $473 million all-cash deal [1] Group 2 - Planet Labs PBC's stock rose 29.7% to $16.79 following better-than-expected third-quarter sales results and an optimistic fourth-quarter sales guidance [2] - Nextdoor Holdings Inc experienced a gain of 22.9% to $3.11 [2] - Gemini Space Station Inc's shares jumped 19.2% to $13.54 after regulatory approval for its subsidiary to offer prediction markets to U.S. customers [2] - Rhythm Pharmaceuticals Inc's stock increased by 13.5% to $119.00 after announcing preliminary results from a Phase 2 trial for setmelanotide in Prader-Willi syndrome patients [2] - Candel Therapeutics Inc gained 12.4% to $6.52 [2] - VersaBank's shares rose 12.34% to $14.52 [2] - Perpetua Resources Corp's stock increased by 10.4% to $28.37 [2] - iHeartMedia Inc jumped 10.1% to $5.19 [2] - NovaBay Pharmaceuticals Inc gained 9.5% to $2.65 [2] - Idaho Strategic Resources Inc's shares rose 9.3% to $43.62 [2] - Immunovant Inc's stock increased by 8.5% to $25.57 after pricing a $550 million common stock offering [2] - Vail Resorts Inc gained 8.3% to $153.30 following first-quarter results [2] - Mosaic Co's shares surged 7.2% to $25.47 amid higher fertilizer stock prices after reports of Ukraine attacking Russian fertilizer plants [2] - Wayfair Inc's stock rose 6.9% to $99.76 [2] - Centene Corp gained 5.3% to $40.72 [2]

Summary of Candel Therapeutics R&D Day Conference Call Company Overview - **Company**: Candel Therapeutics (NasdaqGM:CADL) - **Focus**: Development of viral immunotherapies for difficult-to-treat solid tumors, specifically CAN-2409 and CAN-3110 [2][5] Key Programs and Clinical Trials CAN-2409 - **Description**: Off-the-shelf immunotherapy targeting pan-solid tumors, particularly localized prostate cancer. - **Clinical Trial**: Phase 3 trial with 745 patients, met primary endpoint of disease-free survival, showing a 30% risk reduction in disease recurrence [2][63]. - **FDA Designations**: Received Fast Track and RMAT designations, indicating significant potential for breakthrough therapy [3]. - **Results**: - 38% reduction in prostate cancer recurrence risk [65]. - 80.4% of patients free of prostate cancer at two years post-radiotherapy [67]. - **Administration**: Involves three courses of intraprostatic injections combined with standard care radiotherapy [62]. CAN-3110 - **Description**: A replication-competent herpes simplex virus designed for oncolytic therapy, targeting recurrent high-grade glioma. - **Results**: Promising data published in high-impact journals, indicating potential for other tumors expressing Nestin [6]. Financial Position - **Cash Reserves**: $87 million as of September 2025, with a runway into Q1 2027 [6]. - **Loan Facility**: Entered a term loan facility with Trinity Capital for up to $130 million [7]. Industry Insights and Future Directions - **Immunotherapy Trends**: Discussion on the importance of understanding immune responses and the need for longitudinal studies to improve patient selection for therapies [19][20]. - **Combination Therapies**: Emphasis on the potential of combining immunotherapies with standard treatments and the need for innovative trial designs to test combinations effectively [40][41]. - **Emerging Technologies**: Interest in RNA vaccines and epigenetic pathways as future avenues for enhancing immunotherapy efficacy [34][36]. Challenges and Considerations - **Clinical Trial Design**: Need for smaller, more adaptive trials to better understand the mechanisms of action and patient responses [44][50]. - **Data Integration**: Importance of integrating computational biology and big data analytics to uncover hidden signals in tumor responses [51][54]. Conclusion - Candel Therapeutics is positioned to address significant unmet needs in cancer treatment, particularly with its lead asset CAN-2409, which has shown promising clinical results. The company is focused on innovative trial designs and combination therapies to enhance treatment outcomes for patients with solid tumors [58][60].

Summary of Candel Therapeutics Conference Call Company Overview - **Company**: Candel Therapeutics (NasdaqGM:CADL) - **Focus**: Development of viral immunotherapies for difficult-to-treat cancers, specifically targeting solid tumors [2][3] Key Products CAN-2409 - **Type**: First-in-class in situ vaccination for solid tumors - **Administration**: Requires only 2-3 administrations in a patient's lifetime to achieve durable anti-tumor immunity [3][10] - **Clinical Trials**: - **Phase III Trial**: Conducted in newly diagnosed localized prostate cancer, meeting primary endpoint with a 30% improvement in disease-free survival [17][18] - **Secondary Endpoint**: Achieved a 38% improvement in prostate cancer-specific disease-free survival [18] - **Pathological Complete Response**: 80.4% in CAN-2409 group vs. 63.6% in control group [18] - **FDA Designations**: Fast-track and orphan drug designations for prostate and pancreatic cancers [3][4] CAN-3110 - **Type**: Next-generation oncolytic virus targeting recurrent high-grade glioma - **Mechanism**: Replication-competent herpes simplex virus that selectively replicates in tumor cells [4][26] - **Clinical Data**: Early results show long-term survival in patients with recurrent glioblastoma, with some surviving over 59 months post-treatment [28][29] Financial Position - **Funding**: Recently secured a deal with Trinity Capital for up to $130 million to support clinical trials [22] - **Equity Deals**: Raised funds in December and the first half of the current year [5] Clinical Strategy - **Target Population**: Focus on patients with intermediate or high-risk prostate cancer who prefer curative options over radical surgery or radiotherapy [11][12] - **Trial Design**: Randomized controlled trials with a focus on disease-free survival as the primary endpoint [14][20] - **Patient Experience**: Administration of CAN-2409 is less traumatic than standard biopsies, with most patients reporting it as better tolerated [16][19] Future Plans - **BLA Submission**: Planned for Q4 next year, with ongoing preparations for commercial manufacturing and pre-commercialization activities [20][21] - **Upcoming Trials**: Phase III trial for CAN-2409 in non-small cell lung cancer to start in Q2 next year [24][30] - **Data Generation**: Continued follow-up on prostate cancer trial patients and new data on CAN-3110 expected [30] Important Insights - **Market Position**: Candel Therapeutics is positioned uniquely in the market with no direct competition in the newly diagnosed localized prostate cancer space [11] - **Long-term Survival**: Promising data on long-term survival rates in patients treated with CAN-3110, indicating potential for significant advancements in treatment options for glioblastoma [28][29] - **Scientific Rigor**: Emphasis on independent peer review and collaboration with leading experts in oncology to ensure high-quality research and development [6][30]

Core Insights - Candel Therapeutics, Inc. will host a virtual Research and Development (R&D) Event on December 5, 2025, focusing on its viral immunotherapy approach and oncology pipeline [1][2] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [11][12] - The company has two clinical-stage platforms based on genetically modified adenovirus and HSV gene constructs, with CAN-2409 as the lead candidate from the adenovirus platform [12][13] R&D Event Details - The R&D Day will feature presentations from executive leadership, clinical investigators, and scientific advisors, providing an overview of the company's pipeline [2] - Key presentations will include an introduction by Paul Peter Tak, CEO, and discussions on immuno-oncology innovations [2][3] Product Candidates - CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV-tk gene to tumors, showing potential for treating a broad range of solid tumors [9] - More than 1,000 patients have been dosed with CAN-2409 in clinical trials, demonstrating a favorable tolerability profile [9][12] - CAN-3110 is a first-in-class, replication-competent HSV-1 oncolytic viral immunotherapy candidate, currently in a phase 1b clinical trial for recurrent high-grade glioma [10][13] Clinical Trials and Regulatory Designations - Candel has completed successful phase 2a trials for CAN-2409 in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and a pivotal phase 3 trial in localized prostate cancer [12] - The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to CAN-2409 for various cancer treatments [12]